Not sure how much "ire" there is or why it would even be brought up at this point. One drug continues to increase test scores consistently in the non memantine population and is now backed by the NIH. The other ran a 5 year non controlled trial that only helped 2 patients out of 30+. As for PD, I won't even get started on why the trial continues to drag on but I'm sure they'll slice and dice the data (probably why results have been delayed) until they find something while failing top line results. The funny thing will be seeing folks justify the cherry picking but claim NTRP is a failure for missing top line while actually improving test scores in pre specified groups of 80% of non memantine patients in 2 trials now. C'est la vie. Patience is key.
News 
Market Data 
Discover 
